Abstract
Sjögren's syndrome is a systemic autoimmune disease involving the exocrine glands. In the course of the disease, in parallel with the systemic manifestations, lymphoproliferative disorders frequently. The risk of developing lymphomas in patients with Sjögren's syndrome is increased up to 44 times compared to the rest of the population. Among them, MALT-lymphomas, which have an indolent course, occupy a special place. Genetic factors, immune processes and chronic inflammation play a role in the basis of the malignant transformation of the disease, especially the site of infection with Helicobacter pylori.
References
-
1. Thieblemont C, Bertoni F, Copie-Bergman C, Ferreri AJ, Ponzoni M. Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Semin Cancer Biol. 2014;24:33–42.
2. Vazquez A, Khan MN, Sanghvi S, Patel NR, Caputo JL, Baredes S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009. Head Neck. 2015;37(1):18–22.
3. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029–38.
4. Bende RJ, van Maldegem F, van Noesel CJ. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica. 2009;94(8):1109–23.
5. Jackson AE, Mian M, Kalpadakis C, Pangalis GA, Stathis A, Porro E, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41). Oncologist. 2015;20(10):1149–53.
6. Isaacson PG. Mucosa-associated lymphoid tissue lymphoma. Semin Hematol. 1999;36(2):139–47.
7. Khalil MO, Morton LM, Devesa SS, Check DP, Curtis RE, Weisenburger DD, et al. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol. 2014;165(1):67–77.
8. Kang LY, Ho SP, Chou YP. Primary thymic mucosa-associated lymphoid tissue lymphoma with multiple thin walled lung cysts: case report and literature review. Chin J Cancer Res. 2013;25(3):354–7.
9. Shimizu K, Ishii G, Nagai K, Yokose T, Ishizawa K, Tamaru J, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the thymus: report of four cases. Jpn J Clin Oncol. 2005;35(7):412–6.
10. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol. 2000;24(5): 623–39.
11. LIANG Y, YANG Z, QIN B, ZHONG R: Primary Sjögren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2014; 73: 1151-6. https://doi.org/10.1136/annrheumdis-2013-203305
12. EKSTROM SMEDBY K, VAJDIC CM, FAL¬STER M et al.: Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Con-sortium. Blood 2008; 111: 4029-38. https://doi.org/10.1182/blood-2007-10-119974
13. NOCTURNE G, MARIETTE X: Sjögren Syn¬drome-associated lymphomas: an update on pathogenesis and management. Br J Hae¬matol 2015; 168: 317-27. https://doi.org/10.1111/bjh.13192
14. HERNÁNDEZ-MOLINA G, KOSTOV B, BRI¬TO-ZERÓN P et al.: Characterization and outcomes of 414 patients with primary SS who developed hematological malignancies. Rheumatology (Oxford) 2022 Apr 6. https://doi.org/10.1093/rheumatology/keac205
15. KANG J, KIM H, KIM J et al.: Risk of ma¬lignancy in Korean patients with primary Sjögren’s syndrome. Int J Rheum Dis 2020; 23: 1240-7. https://doi.org/10.1111/1756-185x.13927
16. RETAMOZO S, ACAR-DENIZLI N, HORVÁTH IF et al.: Influence of the age at diagnosis in the disease expression of primary Sjögren’s syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clin Exp Rheumatol 2021; 39 (Suppl. 133): S166-74. https://doi.org/10.55563/clinexprheumatol/egnd1i
17. BJÖRK A, MOFORS J, WAHREN-HERLENIUS M: Environmental factors in the pathogene¬sis of primary Sjögren’s syndrome. J Intern Med 2020; 287: 475-92. https://doi.org/10.1111/joim.13032
18. BRITO-ZERON P, ACAR-DENIZLI N, NG W-F et al.: How immunological profile drives clinical phenotype of primary Sjögren’s syn¬drome at diagnosis: analysis of 10,500 pa¬tients (Sjögren Big Data Project). Clin Exp Rheumatol 2018; 36 (Suppl. 112): S102-12.
19. BRITO-ZERON P, RETAMOZO S, RAMOS-CASALS M: Phenotyping Sjögren’s syn-drome: towards a personalised management of the disease. Clin Exp Rheumatol 2018; 36 Suppl. 112):198-209.
20. VALIM V, SECCO A, DE OLVEIRA FR et al.: Parotid gland swelling in primary Sjögren’s syndrome: activity and other sialadenosis causes. Rheumatology (Oxford) 2022; 61: 2987-92. https://doi.org/10.1093/rheumatology/keab816
21. VASAITIS L, NORDMARK G, THEANDER E et al.: Comparison of patients with and without pre-existing lymphoma at diagno¬sis of primary Sjögren’s syndrome. Scand J Rheumatol 2019; 48: 207-12. https://doi.org/10.1080/03009742.2018.1523456
22. TOMI A-L, BELKHIR R, NOCTURNE G et al.: Brief report: Monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjögren’s syndrome. Arthritis Rheumatol 2016; 68: 1245-50. https://doi.org/10.1002/art.39534
23. RETAMOZO S, BRITO-ZERÓN P, RAMOS-CASALS M: Prognostic markers of lym-phoma development in primary Sjögren syndrome. Lupus 2019; 28: 923-36. https://doi.org/10.1177/0961203319857132
24. BRITO-ZERON P, RAMOS-CASALS M, NAR¬DI N et al.: Circulating monoclonal immu¬noglobulins in Sjögren syndrome. Medicine (Baltimore) 2005; 84: 90-7. https://doi.org/10.1097/01.md.0000157398.37679.47
25. TALAL N, BUNIM JJ: The development of malignant lymphoma in the course of Sjögren’s syndrome. Am J Med 1964; 36: 529-40. https://doi.org/10.1016/0002-9343(64)90101-9
26. RETAMOZO S, GHEITASI H, QUARTUCCIO L et al.: Cryoglobulinaemic vasculitis at diag¬nosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheu¬matology (Oxford) 2016; 55: 1443-51. https://doi.org/10.1093/rheumatology/kew194
27. QUARTUCCIO L, BALDINI C, PRIORI R et al.: Cryoglobulinemia in Sjögren syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosa-associated lym¬phoid tissue. J Rheumatol 2017; 44: 1179- 83. https://doi.org/10.3899/jrheum.161465
28. BRITO-ZERON P, RAMOS-CASALS M, BOVE A, SENTIS J, FONT J: Predicting adverse out¬comes in primary Sjögrensyndrome: identi¬fication of prognostic factors. Rheumatol¬ogy (Oxford) 2007; 46: 1359-62.https://doi.org/10.1093/rheumatology/kem079
29. NOCTURNE G, VIRONE A, NG W-F et al.: Rheumatoid factor and disease activity are independent predictors of lymphoma in pri¬mary Sjögren’s syndrome. Arthritis Rheu-matol 2016; 68: 977-85. https://doi.org/10.1002/art.39518
30. ANDERSON LG, CUMMINGS NA, ASOFSKY R et al.: Salivary gland immunoglobulin and rheumatoid factor synthesis in Sjögren’s syn¬drome. Natural history and response to treat¬mentAm J Med 1972; 53: 456-63. https://doi.org/10.1016/0002-9343(72)90141-6
31. SISÓ-ALMIRALL A, MEIJER JM, BRITO-ZERÓN P et al.: Practical guidelines for the early diagnosis of Sjögren’s syndrome in primary healthcare. Clin Exp Rheumatol 2021; 39 (Suppl. 133): S197-205. https://doi.org/10.55563/clinexprheumatol/pal3z7
32. Sugimoto KJ, Asahina M, Shimada A, Ichikawa K, Wakabayashi M, Sekiguchi Y, et al. IgG3 subclass-positive primary thymic MALT lymphoma without trisomy 3 and trisomy 18: report of a case and review of literature. Int J Clin Exp Pathol. 2014;7(12):8980–7.
33. BRITO-ZERON P, ACAR-DENIZLI N, ZEHER M et al.: Influence of geolocation and eth¬nicity on the phenotypic expression of pri¬mary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis 2017; 76: 1042-50. https://doi.org/10.1136/annrheumdis-2016-209952
34. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000;96(2):410–9.
35. Pereira MI, Medeiros JA. Role of Helicobacter pylori in gastric mucosaassociated lymphoid tissue lymphomas. World J Gastroenterol. 2014;20(3): 684–98.
36. Asenjo LM, Gisbert JP. Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic review. Rev Esp Enferm Dig. 2007;99(7):398–404.
37. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994; 330(18):1267–71.
Downloads
Download data is not yet available.